The Role of p53 in the Regulation of Cancer Stem Cells of Glioblastoma

Michael Karsy

ISBN 10: 3848487535 / ISBN 13: 9783848487530

Published by LAP LAMBERT Academic Publishing Feb 2014, 2014

About this Item

This item is printed on demand - Print on Demand Titel. Neuware -Glioblastoma (GBM) is the most common primary brain tumor and yields a poor prognosis despite current surgical, radiological and chemotherapeutic regimens. Recent studies have provided evidence that the presence of cancer stem cells (CSC) may be responsible for GBM regrowth, dissemination and resistance to therapy. Various genetic abnormalities have been observed in GBM, such as loss of PTEN and NF1, EGFR amplification, as well as p53 mutation, which may be involved in the regulation of CSCs in GBM. This book showed that a codon-specific p53 mutation is associated with the tumorigenesis of GBM as well as regulation of CSC self-renewal and differentiation. In addition, the PTEN/AKT/mTOR and Ras/ERK1/2 signaling pathways are associated with gliomagenesis. Lastly, GBM cells are affected by therapeutic agents, including inhibitors of mTOR, PI3K and ERK1/2, along with arsenic trioxide (ATO) and all- trans retinoic acid (ATRA). The findings of this study highlight the significance of mutant p53, the role of the MAPK and mTOR signaling pathways in the regulation of CSCs, as well as the potential of ATO and ATRA as targeted treatments of GBM.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 256 pp. Englisch.

Seller Inventory # 9783848487530

Bibliographic Details

• Title: The Role of p53 in the Regulation of Cancer Stem Cells of Glioblastoma
• Publisher: LAP LAMBERT Academic Publishing Feb 2014
• Publication Date: 2014
• Language: English
• ISBN 10: 3848487535
• ISBN 13: 9783848487530
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 220W x 150H x 16D millimeters 220 millimeters width by 150 millimeters height by 16 millimeters depth
• Weight: 399 grams

About this title

Synopsis

Glioblastoma (GBM) is the most common primary brain tumor and yields a poor prognosis despite current surgical, radiological and chemotherapeutic regimens. Recent studies have provided evidence that the presence of cancer stem cells (CSC) may be responsible for GBM regrowth, dissemination and resistance to therapy. Various genetic abnormalities have been observed in GBM, such as loss of PTEN and NF1, EGFR amplification, as well as p53 mutation, which may be involved in the regulation of CSCs in GBM. This book showed that a codon-specific p53 mutation is associated with the tumorigenesis of GBM as well as regulation of CSC self-renewal and differentiation. In addition, the PTEN/AKT/mTOR and Ras/ERK1/2 signaling pathways are associated with gliomagenesis. Lastly, GBM cells are affected by therapeutic agents, including inhibitors of mTOR, PI3K and ERK1/2, along with arsenic trioxide (ATO) and all- trans retinoic acid (ATRA). The findings of this study highlight the significance of mutant p53, the role of the MAPK and mTOR signaling pathways in the regulation of CSCs, as well as the potential of ATO and ATRA as targeted treatments of GBM.